Chinese researchers develop immunotherapeutic agent for colon cancer
Release time:2024-05-21 06:56:16
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for 。
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for treating colon cancer, according to a recent article in the academic journal ACS Nano. In animal experiments, the agent, upon successful entry into tumor cells, can enhance T cell effector function to kill tumor cells and suppress colon tumor growth, according to Lu Chunwan from the School of Life Sciences of Tianjin University, one of the authors of the article. The agent can enhance tumor immunogenicity and inhibit colon tumor growth, with no significant impact on normal cells, said Lu. Colon cancer, characterized by its long latency period and high mortality rate, poses a severe threat to human health. Among various therapies, immunotherapy is considered one of the most promising treatment directions, according to Lu.
(Editor:Fu Bo)
Related articles
Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
NEW YORK (AP) — Donald Trump said Friday his campaign has accepted an invitation from Fox News for h2024-05-21Xi Sends Congratulatory Letter to Annual Conference of Cross
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21China contributes over 50% growth to global renewable energy capacity in 2023
(ECNS) -- Global renewable energy installed capacity reached 510 gigawatt last year, with more than2024-05-21Vietnam mulls own territorial line in Tonkin Gulf — Radio Free Asia
Hanoi authorities are considering a baseline marking Vietnam’s territory in the Gulf of Tonkin, Radi2024-05-21College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
The field for the NCAA baseball tournament will take shape this week with conference tournaments det2024-05-21- The prototype of China's self-developed and the world's first four-seater hydrogen-fueled internal c2024-05-21
atest comment